San Francisco and its hotel industry are partnering to beef up security around this week's 43rd annual J.P. Morgan Healthcare ...
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...
Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.
The stock's rise snapped a five-day losing streak.
This was the stock's fourth consecutive day of losses.
Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...
Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...
Gilead’s potential investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor ...
Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $89.88 which represents a slight increase of $0.74 or 0.83% from the prior close of $89.14. The stock opened at $90.19 and ...
Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This ...
Hosted on MSN3d
Morgan Stanley Upgrades Gilead Sciences (GILD)Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback